Kephera seeks volunteers who are confirmed COVID-19 positive to donate finger prick blood samples to help develop a new COVID-19 antibody test.

Kephera seeks volunteers who are confirmed COVID-19 positive to donate finger prick blood samples to help develop a new COVID-19 antibody test. Framingham, MA, April 24, 2020…….Kephera Diagnostics has launched a new study aimed at collecting blood samples from  volunteers at least 18 years of age who have been confirmed positive for COVID-19, for use…

NIAID awards grant to Kephera Diagnostics for point-of-care test for Neurocysticercosis

NIAID awards grant to Kephera Diagnostics for point-of-care test for Neurocysticercosis Framingham, MA – January 13, 2020.  Kephera Diagnostics has been awarded a two-year, $600,000 Phase I SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop a point-of-care test for Neurocysticercosis, the company announced today.  Neurocysticercosis is an infection of…

Kephera Diagnostics awarded contract from the National Cancer Institute for development of a test for parasite linked to a rare cancer

Kephera Diagnostics awarded contract from the National Cancer Institute for development of a test for parasite linked to a rare cancer The National Cancer Institute, an agency of the National Institutes of Health, has awarded a Phase I Small Business Innovative Research (SBIR) contract to Kephera Diagnostics (Framingham, MA) for $299,997 to develop a test for liver…

National Institutes of Health awards grant for novel test-of-cure for Chagas disease

National Institutes of Health awards grant for novel test-of-cure for Chagas disease Framingham, MA – July 16, 2019.  The National Institute of Allergy and Infectious Diseases, an agency of the National Institutes of Health (NIH), has awarded a two-year, $594,008 Small Business Innovative Research (SBIR) grant to Kephera Diagnostics to develop a test-of-cure for Chagas…

Centers for Disease Control awards contract to Kephera Diagnostics for point-of-care test for Taeniasis

Framingham, MA – November 13, 2018.  Kephera Diagnostics has won a $150,000 Phase I SBIR contract from the U.S. Centers for Disease Control and Prevention (CDC) to develop a point-of-care test for Taeniasis, the company announced today.  The Phase I contract will support the generation of key immunological reagents with which the test will be…

National Institutes of Health awards grant to Kephera Diagnostics for new point-of-care test for Chagas disease

Framingham, MA – September 18, 2018.  The National Institute of Allergy and Infectious Diseases, an agency of the National Institutes of Health (NIH), has awarded a two-year, $599,316 SBIR grant to Kephera Diagnostics to develop a new test for Chagas disease, the company announced today.  Under the SBIR grant program, this Phase I grant is…